2. Academic Validation
  3. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer

A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer

  • Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440. doi: 10.1073/pnas.1816626116.
Natasha C Lucki 1,  Genaro R Villa 2 3,  Naja Vergani 1 4,  Michael J Bollong 4,  Brittney A Beyer 1 4,  Jae Wook Lee 4 5,  Justin L Anglin 1,  Stephan H Spangenberg 4,  Emily N Chin 4,  Amandeep Sharma 4,  Kevin Johnson 6,  Philipp N Sander 4,  Perry Gordon 6,  Stephen L Skirboll 7,  Heiko Wurdak 8,  Peter G Schultz 9 4,  Paul S Mischel 10,  Luke L Lairson 11
Affiliations

Affiliations

  • 1 California Institute for Biomedical Research, La Jolla, CA 92037.
  • 2 Department of Molecular and Medical Pharmacology, Medical Scientist Training Program, David Geffen UCLA School of Medicine, Los Angeles, CA 90095.
  • 3 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093.
  • 4 Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037.
  • 5 Natural Constituents Research Center, Korea Institute of Science and Technology, Gangneung, 25451 Gangwon-do, South Korea.
  • 6 Genomics Institute of the Novartis Research Foundation, San Diego, CA 92121.
  • 7 Department of Neurosurgery, Section of Neurosurgery, Veterans Affairs Palo Alto Health Care System, Stanford University, Palo Alto, CA 94304.
  • 8 Institute of Cancer and Pathology, University of Leeds, St. James's University Hospital, LS9 7TF Leeds, United Kingdom.
  • 9 California Institute for Biomedical Research, La Jolla, CA 92037; schultz@scripps.edu pmischel@ucsd.edu llairson@scripps.edu.
  • 10 Ludwig Institute for Cancer Research, University of California, San Diego, La Jolla, CA 92093; schultz@scripps.edu pmischel@ucsd.edu llairson@scripps.edu.
  • 11 Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037; schultz@scripps.edu pmischel@ucsd.edu llairson@scripps.edu.
PMID: 30846550 DOI: 10.1073/pnas.1816626116
Abstract

Glioblastoma multiforme (GBM; grade IV astrocytoma) is the most prevalent and aggressive form of primary brain Cancer. A subpopulation of multipotent cells termed GBM Cancer Stem Cells (CSCs) play a critical role in tumor initiation, tumor maintenance, metastasis, drug resistance, and recurrence following surgery. Here we report the identification of a small molecule, termed RIPGBM, from a cell-based chemical screen that selectively induces Apoptosis in multiple primary patient-derived GBM CSC cultures. The cell type-dependent selectivity of this compound appears to arise at least in part from redox-dependent formation of a proapoptotic derivative, termed cRIPGBM, in GBM CSCs. cRIPGBM induces Caspase 1-dependent Apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a molecular switch, which reduces the formation of a prosurvival RIPK2/TAK1 complex and increases the formation of a proapoptotic RIPK2/Caspase 1 complex. In an orthotopic intracranial GBM CSC tumor xenograft mouse model, RIPGBM was found to significantly suppress tumor formation in vivo. Our chemical genetics-based approach has identified a drug candidate and a potential drug target that provide an approach to the development of treatments for this devastating disease.

Keywords

chemical genetics; glioblastoma; phenotypic drug screening; receptor-interacting protein kinase 2; target identification.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z